Should the industry pin its hopes on Trump’s pick for US FDA commissioner?

Interest from the nicotine-alternatives industry in US president-elect Donald Trump’s pick for Food and Drug Administration (FDA) commissioner, Martin Makary, is less about who he is and more about who he is not.

Many industry members are fed up with multi-term incumbent Robert Califf, who they perceive as a significant roadblock in the process for approving new tobacco products and a general opponent of vaping as well as other reduced-risk categories.

Read full article
I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the TobaccoIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation